Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Frost & Sullivan Applauds MDxHealth for its Proprietary Epigentic DNA-based Technology that Accelerates Cancer Diagnostic Development - MDxHealth's technology drives proprietary product development; prostate cancer confirmation test to be commercialized in 1H2012 - MDxHealth.com
Frost & Sullivan Applauds MDxHealth for its Proprietary Epigentic DNA-based Technology that Accelerates Cancer Diagnostic Development

 

PRZOOM - /newswire/ - London, United Kingdom, 2012/01/09 - MDxHealth's technology drives proprietary product development; prostate cancer confirmation test to be commercialized in 1H2012 - MDxHealth.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the molecular diagnostics for oncology market, Frost & Sullivan recognizes MDxHealth with the 2011 Europe Frost & Sullivan Award for Technology Leadership. MDxHealth's epigenetic platform, the methylation-specific-polymerase chain reaction (PCR) (MSP), can detect the presence of a single cancer cell from almost 10,000 cells with high accuracy and specificity.

MDxHealth's platform offers physicians a novel molecular gene-based technology that uses individual genes as DNA biomarkers and methylation-based molecular diagnostics (MDx) to identify certain gene modifications caused by the presence of cancerous cells. By leveraging the importance of a platform-independent approach, the company has gained expertise in working with a broad spectrum of PCR platforms and therefore, is able to perform assays on a variety of commonly used devices.

MDxHealth works on two principal applications categories: clinical diagnostics, aimed at helping physicians accurately detect and offer prognosis, and pharmaco diagnostics, aimed at assisting pharmaceutical companies in developing companion diagnostics for multiple cancer therapeutics.

The company provides a combination of the most appropriate assays for each type of cancer. Its three main product categories are ConfirmMDx, to determine of the presence or absence of cancer cells; InformMDx, to provide prognostic assessment in distinguishing between aggressive and non-aggressive tumours; and PredictMDx, to indicate which drug or treatment regimen should be addressed to accomplish an effective therapy.

"MDxHealth's tests help distinguish between different levels of drug responders, while helping to accelerate the pharmaceutical development of a variety of drug therapies and demonstrating higher drug efficacy rates," said Frost & Sullivan Senior Research Analyst Cecilia Van Cauwenberghe. "Such new dynamic work styles enable the companies to overcome regulatory issues expediently, while simultaneously diminishing drug discovery and development costs."

The company also drives a pharmaco molecular diagnostics program focused on providing innovative biomarker development services to Biopharma companies to support their drug development programmes and improve their results. MDxHealth's ability to develop and validate highly customized assays significantly helps meet partners' needs in their R&D programs by offering them a reliable and high-performance technology.

MDxHealth's DNA preparation process adheres to a strict quality policy that governs each step of the process. It is this attention to detail that has enabled it to meet ISO 9001 specifications and own the most widely used and cited methylation detection technology in the world.

Another factor that has contributed significantly to MDxHealth's success is its strong IP portfolio, which comprises more than 40 issued patents in multiple countries. The company has established a solid out-licensing and partnering policy by offering numerous opportunities to specialized third-party companies. By this arrangement, the third-party companies can draw up different licensing agreements for some of its technology components to develop applications not pursued by MDxHealth.

Licensing opportunities are open for screening and recurrence monitoring of bladder cancer, colorectal cancer screening, cervical cancer screening and triage, melanoma, ovarian, lung, and breast cancer, in addition to non-cancer diseases that can make use of the DNA methylation process for their diagnosis.

The company's business strategy and its commitment to providing ground-breaking solutions have given a huge boost to its growth rates. In 2010 alone, MDxHealth generated over €2.0 million in product sales and services agreements, which was an increase of 91 per cent over 2009. It gained this competitive edge and market position through strategic investments in technology and business development.

"The company also made a conscious effort to move away from a discovery/license model to a commercial/sales model, and consolidated a strengthened advisory board and management team," noted Van Cauwenberghe. "MDxHealth maintains a strong partnership and collaborations policy, leveraging the robust IP position of the proprietary technology, extensive pipeline, high quality and performance, growing market, clear commercial strategy and profitability to remain successful."

Each year, Frost & Sullivan presents this award to the company that demonstrated excellence in technology leadership within its industry by excelling in all stages of the technology life cycle - incubation, adaptation, take up, and maturity - to ensure a continuous flow of improvements. By innovating leading-edge concepts the company has pioneered client applications.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About MDxHealth

MDxHealth (mdxhealth.com) is a molecular diagnostics company that develops and commercializes advanced tests for cancer assessment and the personalized treatment of patients. MDxHealth is a publicly-listed company trading on the NYSE Euronext markets of Brussels and Amsterdam under the ticker symbol "MDXH". MDxHealth was established in 2003 and is headquartered in Belgium. Its US headquarters is located in Irvine, CA. MDxHealth develops and commercialize molecular diagnostic products on its own or in partnership with pharmaceutical companies. Some of its products are already commercialized and the company has a broad pipeline of other products for major cancer indications.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Applauds MDxHealth for its Proprietary Epigentic DNA-based Technology that Accelerates Cancer Diagnostic Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan | MDxHealth Press Room
Contact: Emily Bailey - Frost.com 
+44(0)20 7915 7869 emily.bailey[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  Triggr & Bloom

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today